Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies. Copyright © 2020 Elsevier Inc. All rights reserved.


Eiichi Ogawa, Mike T Wei, Mindie H Nguyen. Hepatitis B Virus Reactivation Potentiated by Biologics. Infectious disease clinics of North America. 2020 Jun;34(2):341-358

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32334985

View Full Text